Antisoma shares plunge after latest cancer drug setback
Tuesday 01 February 2011
Antisoma suffered a blow last night after it revealed that a key acute leukaemia drug had failed in a final-stage clinical trial.
The biotech firm said it had also halted the development of another cancer treatment after early data from an ongoing penultimate-stage trial showed that the result was likely to be inconclusive.
The news triggered a sharp sell-off in Antisoma's shares, which closed at 2.2p, down more than 64 per cent. The decline leaves the firm valued at around £14m.
Glyn Edwards, Antisoma's chief executive, said the company had not seen a benefit with the AS1413 leukaemia treatment. "This is hugely disappointing for patients, investigators, investors and employees" he said. "We will now become smaller and focus on maximising the value of our other programmes."
Paul Cuddon at the Peel Hunt brokerage said the developments meant that "other than a £23m cash balance, which is continuing to decline, there are few assets left to value in the Antisoma pipeline".
He warned: "Other than 3.5p of cash, which we anticipate will fall to 2p, little value remains in Antisoma, and sadly we fail to see an ongoing future."
Samir Devani at Nomura Code Securities said the failure of the AS1413 final-stage trial was "not a huge surprise" as he had only assumed a 30 per cent chance of success.
The setback did, however, have a "major impact" on Antisoma's valuation, he added.
"We expect the company to go into cash-conserving mode and anticipate a significant restructuring in the near-term," he explained.
The latest setback comes less than a year after Antisoma's key lung cancer drug, ASA404, failed in March.
- 1 Isis 'jihadi bride' claims forced sex with Yazidi girls is never rape because Koran condones it
- 2 Woman accidentally shoots herself in the head while posing for a selfie
- 3 Art Garfunkel: Paul Simon is a 'monster' with a Napoleon complex
- 4 Isis burns woman alive for refusing to engage in 'extreme' sex act, UN says
Isis 'jihadi bride' claims forced sex with Yazidi girls is never rape because Koran condones it
Woman accidentally shoots herself in the head while posing for a selfie
Isis burns woman alive for refusing to engage in 'extreme' sex act, UN says
Puerto Rico, island of lost dreams: People are leaving the debt-hit territory in droves as near neighbour Cuba's star rises
16-year-old girl beaten and burned alive by lynch mob in Rio Bravo, Guatemala
As a white man, I'm surprised more women aren't tweeting the hashtag #KillAllWhiteMen
Scotland may have to leave the EU even if it votes to stay in, David Cameron confirms
The day that Britain resigned as a global power
Almost a third of school pupils believe 'Muslims are taking over our country', study claims
SNP fury as HS2 finds 'no business case' for taking fast train service to Scotland
Gay marriage 'Bert and Ernie' cake bakery found guilty of discrimination in Northern Ireland
iJobs Money & Business
£40-50K: Guru Careers: We are seeking an experienced Software / C# Developer w...
£45,000 - £55,000: Neil Pavier: Are you looking for your next opportunity for ...
£45,000 - £55,000: Sheridan Maine: Are you a newly qualified ACA/ACCA/ACMA qua...
£50,000 - £60,000: Laura Norton: Are you looking for an opportunity within a w...